Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 65Stomach Neoplasms 14Colonic Neoplasms 10Rectal Neoplasms 5Triple Negative Breast Neoplasms 3Sarcoma 3Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2NSCLC 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Colorectal Cancer Metastatic 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Advanced Solid Tumors 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1TAS 102 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Platinum Resistant Ovarian Cancer 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Metastatic Colorectal Adenocarcinoma 1

Interventions

Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Bevacizumab 2Temozolomide 1Radiotherapy 1Phlebotomy 1Pharmaceutical Preparations 1Nivolumab 1HMPL-013 1Fluoxetine 1Cisplatin 1Cholecalciferol 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Adenocarcinoma × HMPL-013 × Clear all
NCT05635149 2022-12-02

Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Unknown
100 enrolled
Gastrointestinal

Colorectal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡